Nebulized anticoagulants limit coagulopathy but not inflammation in pseudomonas aeruginosa-induced pneumonia in rats

Shock

Volumn 36, Issue 4, 2011, Pages 417-423

  Cornet, Alexander D ^a,b   Hofstra, Jorrit J ^a,c,d   Vlaar, Alexander P ^a,c,d   Van Den Boogaard, Floor E ^a   Roelofs, Joris J ^a   Van Der Poll, Tom ^d   Levi, Marcel ^d   Groeneveld, A B Johan ^b   Schultz, Marcus J ^a,c,e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Department of Intensive Care Medicine ^*  (Netherlands)

^d Center for Experimental and Molecular Medicine (CEMM)   (Netherlands)

^e HERMES Critical Care Group   (Netherlands)

Author keywords

administration by inhalation; antithrombin; coagulation; danaparoid; fibrinolysis; heparin; Pneumonia; protein C; Pseudomonas aeruginosa

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; DANAPAROID; DROTRECOGIN; FIBRIN DEGRADATION PRODUCT; HEPARIN; MONTEPLASE; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; DISEASE ASSOCIATION; FIBRINOLYSIS; IN VIVO STUDY; INFLAMMATION; MALE; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RAT;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; CHONDROITIN SULFATES; DERMATAN SULFATE; FIBRINOLYSIS; HEPARIN; HEPARITIN SULFATE; INFLAMMATION; MALE; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 80052960702     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31822bcef0     Document Type: Article

References (35)

1. Richards MJ, Edwards JR, Culver DH, Gaynes RP: Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 27:887-892, 1999. (Pubitemid 29266004)
2. Hoffken G, Niederman M: Nosocomial pneumonia: the importance of a deescalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 122:2183-2196, 2002. (Pubitemid 36051158)
3. Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med 165:867-903, 2002. (Pubitemid 34774654)
4. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS: Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumoniaVa review. Crit Care Med 34:871-877, 2006.
5. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001. (Pubitemid 32204987)
6. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF: Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 33:952-961, 2005. (Pubitemid 40638163)
7. Yasui H, Gabazza EC, Tamaki S, Kobayashi T, Hataji O, Yuda H, Shimizu S, Suzuki K, Adachi Y, Taguchi O: Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med 163:1660-1668, 2001. (Pubitemid 32578773)
8. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K: Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 272:L197-L202, 1997.
9. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, Tidswell M, Siegel MD, Soto G, Peterson MW, et al.: Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 178: 618-623, 2008.
10. Eisele B, Lamy M, Thijs LG, Keinecke KO, Schuster HP, Matthias FR, Fourrier F, Heinrichs H, Delvos U: Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a metaanalysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 24:663-672, 1998. (Pubitemid 28393397)
11. Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K: Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 93:157-164, 1999. (Pubitemid 29019399)
12. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P: Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 96:2302-2310, 1997. (Pubitemid 27425837)
13. Duensing TD, Wing JS, van Putten JP: Sulfated polysaccharide-directed recruitment of mammalian host proteins: a novel strategy in microbial pathogenesis. Infect Immun 67:4463-4468, 1999. (Pubitemid 29400420)
14. Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, Munoz A: Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med 37:1185-1196, 2009.
15. Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, Traber LD, Schmalstieg FC, Hawkins HK, Herndon DN, et al.: Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 18:236-241, 2002.
16. Darien BJ, Fareed J, Centgraf KS, Hart AP, MacWilliams PS, Clayton MK, Wolf H, Kruse-Elliot KT: Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. Shock 9:274-281, 1998. (Pubitemid 128463295)
17. Hagiwara S, Iwasaka H, Hidaka S, Hishiyama S, Noguchi T: Danaparoid sodium inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats. Crit Care 12:R43, 2008.
18. Hofstra JJ, Cornet AD, de Rooy BF, Vlaar AP, van der Poll T, Levi M, Zaat SA, Schultz MJ: Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats. Crit Care 13:R145, 2009.
19. Hofstra JJ, Vlaar AP, Cornet AD, Dixon B, Roelofs JJ, Choi G, van der Poll T, Levi M, Schultz MJ: Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. J Aerosol Med Pulm Drug Deliv 23:105-111, 2010.
20. Choi G, Hofstra JJ, Roelofs JJ, Florquin S, Bresser P, Levi M, van der Poll T, Schultz MJ: Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 35:1362-1368, 2007. (Pubitemid 46642667)
21. Harada N, Okajima K, Kohmura H, Uchiba M, Tomita T: Danaparoid sodium reduces ischemia/reperfusion-induced liver injury in rats by attenuating inflammatory responses. Thromb Haemost 97:81-87, 2007. (Pubitemid 46242389)
22. Choi G, Hofstra JJ, Roelofs JJ, Rijneveld AW, Bresser P, van der Zee JS, Florquin S, van der Poll T, Levi M, Schultz MJ: Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 36:204-210, 2008.
23. Choi G, Vlaar AP, Schouten M, van 't Veer C, van der Poll T, Levi M, Schultz MJ: Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. Eur Respir J 30:423-428, 2007. (Pubitemid 351182063)
24. Choi G, Schultz MJ, Levi M, van der Poll T: The relationship between inflammation and the coagulation system. Swiss Med Wkly 136:139-144, 2006.
25. Kipnis E, Guery BP, Tournoys A, Leroy X, Robriquet L, Fialdes P, Neviere R, Fourrier F: Massive alveolar thrombin activation in Pseudomonas aeruginosaY induced acute lung injury. Shock 21:444-451, 2004.
26. Robriquet L, Collet F, Tournoys A, Prangere T, Neviere R, Fourrier F, Guery BP: Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir Res 7:41, 2006.
27. Cornet AD, van Nieuw Amerongen GP, Beishuizen A, Schultz MJ, Girbes ARJ, Groeneveld AB: Activated protein C in the treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Drug Discov 4:219-227, 2009.
28. Maybauer MO, Maybauer DM, Fraser JF, Traber LD, Westphal M, Enkhbaatar P, Cox RA, Huda R, Hawkins HK, Morita N, et al.: Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. Crit Care Med 34:2432-2438, 2006. (Pubitemid 44262031)
29. Waerhaug K, Kirov MY, Kuzkov VV, Kuklin VN, Bjertnaes LJ: Recombinant human activated protein C ameliorates oleic acidYinduced lung injury in awake sheep. Crit Care 12:R146, 2008.
30. Waerhaug K, Kuklin VN, Kirov MY, Sovershaev MA, Langbakk B, Ingebretsen OC, Ytrehus K, Bjertnaes LJ: Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep. Crit Care 12:R104, 2008.
31. Esmon CT: Role of coagulation inhibitors in inflammation. Thromb Haemost 86:51-56, 2001. (Pubitemid 32663936)
32. Iba T, Kidokoro A, Fukunaga M, Nagakari K, Suda M, Yoshikawa S, Ida Y: Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin. Intensive Care Med 31:1101-1108, 2005. (Pubitemid 41125342)
33. Dixon B, Santamaria JD, Campbell DJ: A phase 1 trial of nebulised heparin in acute lung injury. Crit Care 12:R64, 2008.
34. Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD: Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care 14:445, 2010.
35. Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ: Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 14:R180, 2010.